Stock Performance and Market Context
On the day the new low was recorded, Sanofi India’s share price fell by 0.97%, underperforming the Pharmaceuticals & Biotechnology sector by 1.39%. The stock is trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the broader market, where the Sensex recovered from an early negative opening to close 0.26% higher at 82,841.21, just 4.01% shy of its 52-week high of 86,159.02.
Over the past year, Sanofi India’s stock has delivered a negative return of 22.85%, markedly lagging the Sensex’s positive 9.09% gain. The stock’s 52-week high was Rs.6717.50, underscoring the extent of the recent decline.
Financial Performance and Growth Trends
Sanofi India’s long-term financial performance has been subdued. Net sales have contracted at an annualised rate of 8.47% over the last five years, while operating profit has declined by 5.55% annually during the same period. The company’s most recent quarterly results, reported in September 2025, showed flat performance, offering little indication of a turnaround in growth momentum.
The stock’s underperformance extends beyond the last year, with returns trailing the BSE500 index over one, three years, and the past three months. This persistent lag reflects challenges in sustaining revenue and profit growth within a competitive pharmaceutical landscape.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Valuation and Dividend Yield
Despite the subdued growth, Sanofi India maintains a relatively attractive valuation profile. The company’s return on equity (ROE) stands at a robust 49.40%, indicating efficient utilisation of shareholder capital. The average debt-to-equity ratio remains at zero, reflecting a conservative capital structure with minimal leverage.
The stock trades at a price-to-book value of 11.9, which is considered very attractive relative to its peers’ historical valuations. At the current price level, the dividend yield is notably high at 4.76%, offering a steady income stream for shareholders amid price volatility.
Institutional Holdings and Market Sentiment
Institutional investors hold a significant 26.86% stake in Sanofi India, suggesting confidence from entities with extensive analytical resources. This level of institutional ownership often reflects a thorough assessment of the company’s fundamentals, despite the recent price weakness.
However, the company’s Mojo Score has deteriorated to 47.0, with a corresponding Mojo Grade downgraded from Hold to Sell as of 5 Feb 2026. This shift reflects a reassessment of the stock’s medium-term prospects based on its financial and market performance.
Sanofi India Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Comparison
Sanofi India operates within the Pharmaceuticals & Biotechnology sector, which has generally shown resilience in recent trading sessions. The sector outperformed the stock on the day of the new low, highlighting a divergence in performance within the industry. While the Sensex and mega-cap stocks led the market higher, Sanofi India’s share price continued to trend downward.
The stock’s underperformance relative to the sector and broader market indices over the past year and longer periods underscores the challenges faced by the company in maintaining competitive positioning and growth.
Summary of Key Metrics
To summarise, Sanofi India’s stock has reached a 52-week low of Rs.3965.55, reflecting a decline of nearly 41% from its 52-week high of Rs.6717.50. The company’s five-year net sales and operating profit have contracted at annual rates of 8.47% and 5.55% respectively. The stock’s Mojo Grade was downgraded to Sell on 5 Feb 2026, with a current Mojo Score of 47.0.
Despite these headwinds, the company maintains a high ROE of 49.40%, a zero average debt-to-equity ratio, and a dividend yield of 4.76%. Institutional investors hold a substantial stake of 26.86%, indicating continued interest from well-resourced market participants.
Overall, the stock’s recent price action and fundamental indicators highlight a period of subdued performance within a generally positive market environment.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
